Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: The integrated data exploratory analysis (IDEA) study

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 48, Issue 5, 2009, Pages 511-518

  Newcorn, Jeffrey H ^a   Sutton, Virginia K ^c   Weiss, Margaret D ^b   Sumner, Calvin R ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c i3 Research

^d BioBehavioral Diagnostics Company   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Mediator; Moderator; Response prediction

Indexed keywords

ATOMOXETINE; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ADHD RATING SCALE IV PARENT VERSION: INVESTIGATOR ADMINISTERED AND SCORED TOTAL SCORE; ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; EVENING DOSAGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; DOSE RESPONSE; PSYCHOLOGICAL RATING SCALE; STATISTICAL MODEL; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ANALYSIS OF VARIANCE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67650290119     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1097/CHI.0b013e31819c55b2     Document Type: Article

References (36)

1. Biederman J, Spencer TJ, Newcorn JH et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl). 2007;190:31-41.
2. Kelsey DK, Sumner CR, Casat CD et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;14:e1Ye8.
3. Kratochvil CJ, Heiligenstein JH, Dittmann R et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
4. Kratochvil CJ, Wilens TE, Greenhill LL et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45: 919-927.
5. Kratochvil CJ, Vaughan BS, Mayfield-Jorgensen ML et al. A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17:175-185.
6. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.
7. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
8. Spencer T, Heiligenstein JH, Biederman J et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63: 1140-1147.
9. McGough J, McCracken J, Swanson J et al. Pharmacogenetics of meth-ylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1314-1322. 2006
10. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46:242-251.
11. Abikoff H, Hechtman L, Klein RG et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43:802-811.
12. Rapport MD, Denney C, DuPaul GJ, Gardner MJ. Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry. 1994;33:882-893.
13. Stein MA, Sarampote CS, Waldman ID et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112:e404.
14. Swanson JM, Kraemer HC, Hinshaw SP et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Child Adolesc Psychiatry. 2001;40:168-179.
15. Hinshaw SP. Moderators and mediators of treatment outcome for youth with ADHD: understanding for whom and how interventions work. J Pediatr Psychol. 2007;32:664-675.
16. March JS, Swanson JM, Arnold LE et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol. 2000;28:527-541.
17. Rieppi R, Greenhill LL, Ford RE et al. Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry. 2002;41:269-277.
18. Owens EB, Hinshaw SP, Kraemer HC et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol. 2003;71:540-552.
19. Greenhill LL, Newcorn JH, Gao H, Feldman PD. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. J Am Acad Child Adolesc Psychiatry. 2007;46:566-572.
20. Newcorn J, Kratochvil C, Allen AJ et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyper-activity disorder: acute comparison and differential response [published online ahead of print February 15, 2008]. Am J Psychiatry. doi:10.1176/appi.ajp. 2007.05091676.
21. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006;29:1573-1585.
22. Carlson GA, Dunn D, Kelsey D et al. A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2007;1:10.
23. Kelsey D, Sutton V, Lewis D, Schuh K, Sumner C, Quintana H. Morning-dosed versus evening-dosed atomoxetine for treating ADHD in children. Presented at Annual Meeting of the American Psychiatric Association; Psychosomatic Medicine: Integrating Psychiatry and Medicine; Atlanta, GA; May 21-26, 2005.
24. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord. 2001;5:39-47.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-R). Washington: American Psychiatric Association; 2000.
26. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158.
27. Gao H, Zhao Y, Levine L, Allen AJ. Determining cut-points for clinically meaningful improvement: a ROC approach. Presented at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry; San Diego; Oct. 24-29, 2006.
28. Chen S, Chou W-H, Blouin RA et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther. 1996;60:522-534.
29. Newcorn JH, Michelson D, Kratochvil CJ, Allen AJ, Ruff DD, Moore RJ. Low-dose atomoxetine for maintenance treatment of attention-deficit/ hyperactivity disorder. Pediatrics. 2006;118:E1701YE1706.
30. Dickson RA, Jackiewicz G, Khattak S et al. Change in ADHD symptoms and functional outcomes in Canadian children during 3 months of atomoxetine treatment. Presented at: World Psychiatric Association International Congress 2007; November 28 to December 2, 2007; Melbourne, Victoria, Australia.
31. Montoya A, Escobar R, Gilalberto I et al. Continued improvement in newly diagnosed children and adolescents with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled trial of atomoxetine. Presented at: 13th International Congress of the European Society for Child and Adolescent Psychiatry (ESCAP); August 25-29, 2007; Florence, Italy.
32. Quitkin FM, McGrath PJ, Stewart JW et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53:785-792.
33. Gordon E, Liddell BJ, Brown KJ et al. Integrating objective gene-brain-behavior markers of psychiatric disorders. J Integr Neurosci. 2007;6: 1-34.
34. Elia J, Welsh PA, Gullotta CS, Rapoport JL. Classroom academic performance: improvement with both methylphenidate and dextroam-phetamine in ADHD boys. J Child Psychol Psychiatry. 1993;34:785-804.
35. Arnsten AF, Scahill L, Findling RL. Alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol. 2007;17: 393-406.
36. Rapoport JL, Inoff-Germain G. Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: update 2002. J Atten Disord. 2002;6:S57YS60.